Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR)
Pragmatic, Randomized, Optimal Platelet and Plasma Ratios (PROPPR)is a Phase III trial designed to evaluate the difference in 24-hour and 30-day mortality among subjects predicted to receive massive transfusion ([MT] (defined as receiving 10 units or more red blood cells (RBCs) within the first 24 hours). The goal of PROPPR is to improve the basis on which clinicians make decisions about transfusion protocols for massively bleeding patients.
PROPPR is a Resuscitation Outcomes Consortium (ROC) Protocol. ROC is funded by the National Heart, Lung, and Blood Institute (NHLBI), the United States' Department of Defense (DoD) and the Defence Research and Development Canada. PROPPR will be conducted as a Phase III trial at Level I Adult Trauma Centers in North America.
|Trauma||Biological: 1:1:1 Blood Transfusion Ratio Biological: 1:1:2 Blood Transfusion Ratio||Phase 3|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Pragmatic, Randomized Optimal Platelet and Plasma Ratios|
- 24-hour Mortality [ Time Frame: First 24 hours after ED admission ]
- 30-day Mortality [ Time Frame: First 30 days after ED admission ]
- Coagulation and Inflammatory Phenotypes at Emergency Department Admission and Over Time. [ Time Frame: 72 hours ]
- Hospital Free Days [ Time Frame: first 30 days after ED admission ]
- Time to Hemostasis [ Time Frame: ED admission to hospital discharge or 30 days, whichever comes first ]Time to hemostasis refers to the time that the subject achieved hemorrhage control (anatomic hemostasis and resuscitation complete)following emergency department (ED) arrival.
- Amount of Randomized Blood Products Given to Hemostasis [ Time Frame: 24 hours from randomization ]
- Functional Status at Time of Hospital Discharge [ Time Frame: Hospital discharge or 30 days, whichever comes first ]The Glasgow Outcome Extended Score (GOSE) is a tool used to measure recovery following brain injury and assists with prediction of long-term rehabilitation. The 8 scoring categories are death, vegetative state, lower severe disability, upper severe disability, lower moderate disability, upper moderate disability, lower good recovery and upper good recovery. A higher GOSE score correlates with better outcome.
- Incidence of Primary Surgical Procedure [ Time Frame: ED admission to hospital discharge or 30 days, whichever comes first ]
- Incidence of Transfusion Related Serious Adverse Events [ Time Frame: ED admission to hospital discharge or 30 days, whichever comes first ]
- Initial Hospital Discharge Status [ Time Frame: Hospital discharge or 30 days, whichever comes first ]
- Ventilator Free Days [ Time Frame: first 30 days after ED admission ]
- ICU Free Days [ Time Frame: first 30 days after ED admission ]
- Amount of Blood Products Given From Hemostasis to 24 Hours After ED Admission [ Time Frame: 24 hours after ED admission ]
|Study Start Date:||August 2012|
|Study Completion Date:||December 2013|
|Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
|Active Comparator: 1:1:1 Blood Transfusion Ratio||
Biological: 1:1:1 Blood Transfusion Ratio
Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.
|Active Comparator: 1:1:2 Blood Transfusion Ratio||
Biological: 1:1:2 Blood Transfusion Ratio
Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.
Background: Multiple observational studies have reported that blood product component ratios (i.e., plasma:platelets:RBCs) that approach the 1:1:1 ratio, found in fresh whole blood, are associated with significant decreases in truncal hemorrhagic death and in overall 24-hour and 30-day mortality among injured patients. The rationale for the 1:1:1 ratio is that the closer a transfusion regimen approximates whole blood, the faster hemostasis will be achieved with minimum risk of coagulopathy. The current DoD guideline specifies the use of 1:1:1, and this practice is followed on almost all combat casualties. In other observational studies, leading centers have reported good outcomes across a range of different blood product ratios. For example, a 1:2 plasma:RBC ratio is used with little guidance regarding platelets. The proposed randomized trial is intended to resolve debate and uncertainty regarding optimum blood product ratios.
Study Design: Randomized, two-group, controlled Phase III trial with a Vanguard stage. Equal random allocation to treatment using stratified, permuted blocks with randomly chosen block sizes and stratification by site.
Objective: To conduct a Phase III multi-site, randomized trial in subjects predicted to have a massive transfusion, comparing the efficacy and safety of 1:1:1 transfusion ratios of plasma and platelets to red blood cells (the closest approximation to reconstituted whole blood) with the 1:1:2 ratio. The co-primary outcomes will be 24-hour and 30-day mortality. The PROPPR Trial will be conducted with exception from informed consent (EFIC). Additionally, laboratory data from the trial will add to the understanding of trauma induced coagulopathy (TIC) and inflammation.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01545232
|United States, Alabama|
|University of Alabama|
|Birmingham, Alabama, United States, 35233|
|United States, Arizona|
|University of Arizona|
|Tucson, Arizona, United States, 85721|
|United States, California|
|University of Southern California, Los Angeles|
|Los Angeles, California, United States, 90033|
|University of California, San Francisco|
|San Francisco, California, United States, 94143|
|United States, Maryland|
|University of Maryland School of Medicine|
|Baltimore, Maryland, United States, 21201|
|United States, Ohio|
|University of Cincinnati|
|Cincinnati, Ohio, United States, 45221|
|United States, Oregon|
|Oregon Health and Science University|
|Portland, Oregon, United States, 97239|
|United States, Tennessee|
|University of Tennessee Health Science Center|
|Memphis, Tennessee, United States, 38103|
|United States, Texas|
|University of Texas Health Science Center- Memorial Hermann Hospital|
|Houston, Texas, United States, 77030|
|United States, Washington|
|University of Washington- Harborview Medical Center|
|Seattle, Washington, United States, 98104|
|United States, Wisconsin|
|Medical College of Wisconsin|
|Milwaukee, Wisconsin, United States, 53226|
|Sunnybrook Health Science Center|
|Toronto, Ontario, Canada, M4N 3M5|
|Study Director:||John Holcomb, MD||The University of Texas Health Science Center, Houston|